Avanos Medical, Inc.
AVNSDelisted Jul 27, 2026- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- SEC CIK
- 0001606498
Avanos Medical, Inc. was delisted on Jul 27, 2026; its insiders filed their last Form 4 on Jul 28, 2026; 290 institutions reported holding it in 13F filings for Q2 2026, worth $1.08B in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:41 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $72.9M (10.4% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 24, 2026 | Feb 26, 2025 | Jan 4, 2024 | Feb 21, 2023 | Feb 23, 2022 |
| Revenue | $701.2M | $687.8M | $673.3M | $820.0M | $744.6M |
| Cost of revenue | $347.3M | $306.5M | $293.6M | $370.0M | $380.3M |
| Gross profit | $353.9M | $381.3M | $379.7M | $450.0M | $364.3M |
| Research and development | $23.3M | $26.2M | $27.2M | $30.6M | $32.3M |
| Selling, general and administrative | $315.6M | $318.5M | $335.0M | $341.9M | $300.3M |
| Operating income | -$61.6M | -$396.2M | $4.20M | $74.0M | $8.90M |
| Interest expense | – | – | $15.0M | $10.0M | $3.30M |
| Income tax | $6.70M | -$17.0M | $2.00M | $14.7M | $600.0K |
| Net income | -$72.9M | -$392.1M | -$61.8M | $50.5M | $5.20M |
| EPS, basic | $-1.57 | $-8.53 | $-1.32 | $1.08 | $0.11 |
| EPS, diluted | $-1.57 | $-8.53 | $-1.32 | $1.07 | $0.11 |
| Weighted shares, basic | 46.3M | 46.0M | 46.6M | 46.9M | 48.1M |
| Weighted shares, diluted | 46.3M | 46.0M | 46.6M | 47.3M | 48.6M |
| Margins and growth | |||||
| Gross margin | 50.5% | 55.4% | 56.4% | 54.9% | 48.9% |
| Operating margin | -8.8% | -57.6% | 0.6% | 9.0% | 1.2% |
| Net margin | -10.4% | -57.0% | -9.2% | 6.2% | 0.7% |
| Revenue growth, year over year | +1.9% | +2.2% | −17.9% | +10.1% | +4.2% |
| Net income growth, year over year | – | – | −222.4% | +871.2% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 24, 2026 | Feb 26, 2025 | Jan 4, 2024 | Feb 21, 2023 | Feb 23, 2022 |
| Cash and equivalents | $89.8M | $107.7M | $87.7M | $127.7M | $118.5M |
| Accounts receivable | $103.8M | $132.8M | $142.8M | $167.9M | $131.2M |
| Inventory | $148.0M | $138.8M | $163.2M | $190.3M | $150.3M |
| Total current assets | $355.4M | $393.4M | $487.0M | $499.8M | $418.6M |
| Property, plant and equipment | $113.4M | $110.7M | $117.2M | $163.9M | $168.1M |
| Goodwill | $394.9M | $455.6M | $796.1M | $819.4M | $801.6M |
| Intangible assets | $117.8M | $112.3M | $239.5M | $251.0M | $141.2M |
| Total assets | $1.07B | $1.15B | $1.69B | $1.79B | $1.59B |
| Accounts payable | $55.5M | $54.3M | $56.3M | $67.9M | $56.4M |
| Short-term debt | $10.2M | $9.40M | $8.60M | $6.20M | – |
| Total current liabilities | $165.2M | $165.9M | $234.6M | $185.8M | $139.2M |
| Long-term debt | $90.3M | $125.3M | $159.4M | $226.3M | $130.0M |
| Total liabilities | $295.5M | $325.7M | $456.1M | $495.7M | $330.7M |
| Shareholders' equity | $778.2M | $828.5M | $1.24B | $1.29B | $1.26B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 24, 2026 | Feb 26, 2025 | Jan 4, 2024 | Feb 21, 2023 | Feb 23, 2022 |
| Operating cash flow | $74.7M | $100.7M | $32.4M | $90.9M | $87.3M |
| Capital expenditures | $31.6M | $17.8M | $17.8M | $19.3M | $21.0M |
| Free cash flow | $43.1M | $82.9M | $14.6M | $71.6M | $66.3M |
| Depreciation and amortization | $38.9M | $45.5M | $46.1M | $47.7M | $38.3M |
| Stock-based compensation | $12.6M | $13.8M | $15.8M | $15.9M | $13.2M |
| Share buybacks | $3.30M | $12.8M | $19.1M | $45.5M | $11.5M |
| Investing cash flow | -$60.6M | -$27.5M | $21.6M | -$135.4M | -$21.0M |
| Financing cash flow | -$37.0M | -$49.1M | -$94.2M | $56.7M | -$55.3M |
| Net change in cash | -$17.9M | $20.0M | -$40.0M | $9.20M | $7.00M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 1.8% | 2.0% | 2.3% | 1.9% | 1.8% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Apr 28, 2026 | 46.8M | +1.3% | SEC |
| Feb 17, 2026 | 46.5M | +1.1% | SEC |
| Oct 29, 2025 | 46.4M | +1.0% | SEC |
| Jul 29, 2025 | 46.4M | +1.0% | SEC |
| Apr 29, 2025 | 46.2M | +0.7% | SEC |
| Feb 19, 2025 | 46.0M | −0.4% | SEC |
| Oct 23, 2024 | 46.0M | −1.0% | SEC |
| Jul 24, 2024 | 45.9M | −2.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.